Future Of TG’s Ukoniq In Question As Drug Attracts Closer FDA Scrutiny
Executive Summary
The agency has suspended enrollment in Ukoniq trials while also hinting at greater scrutiny of “the continued marketing” of the drug.
You may also be interested in...
TG Shifts Focus To MS After Pausing Oncology Programs, Ukoniq Withdrawal
TG Therapeutics is withdrawing the PI3K-delta inhibitor from the market and halting enrolling in other umbralisib oncology studies to focus attention on ublituximab in relapsing multiple sclerosis.
Despite FDA Setback, MEI’s Zandelisib Could Still Break PI3K Curse
MEI/Kyowa Kirin will no longer seek accelerated approval based on a single-arm study as the FDA is calling for Phase III data due to growing conservatism regarding the PI3K class.
2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy
Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.